The nervous system is a steroidogenic tissue and several steroids synthesized locally in the brain, such as pregnenolone, progesterone and estradiol, modulate neuronal and glial physiology and are neuroprotective. The brain upregulates steroidogenesis at sites of injury as part of a program triggered by neural tissue to cope with neurodegenerative insults. Pharmacological targets to increase brain steroidogenesis and promote neuroprotection include the molecules that transport cholesterol to the inner mitochondrial membrane, where the first enzyme for steroidogenesis is located. Furthermore, the human gene encoding aromatase, the enzyme that synthesizes estradiol, is under the control of different tissue-specific promoters, and it is therefore conceivable that selective aromatase modulators can be developed that will enhance the expression of the enzyme and the consequent increase in estrogen formation in the brain but not in other tissues.
synthesized locally. The central nervous system is a steroidogenic tissue that expresses enzymes for steroid synthesis and metabolism. Cholesterol is converted in the brain to pregnenolone and then pregnenolone, at least in rodent brain, can be converted to dehydroepiandrosterone, a precursor of testosterone (1, 2) . Pregnenolone in the nervous system is also converted in progesterone, which in turn is metabolized to dihydroprogesterone and tetrahydroprogesterone (2) . Steroids locally synthesized in the nervous system participate in the regulation of neuronal and glial physiology, synaptic transmission and synaptic plasticity and modulate affection and cognition (2, 3) .
The first step of steroidogenesis, the transformation of cholesterol into pregnenolone, occurs in the mitochondria. The transport of cholesterol to the inner mitochondrial membrane is the rate-limiting step for sex steroid synthesis and is highly regulated. Two proteins located in the mitochondrial membrane, the steroidogenic acute regulatory protein (StAR) (4) and the peripheral-type benzodiazepine receptor, which has been recently renamed as translocator protein (18 kDa) (TSPO) (5) , are involved in this transport.
Another important step in brain steroid metabolism is the conversion of testosterone in estradiol. Testosterone and other C19 steroids are converted in estradiol by aromatase, an enzyme that consists of two components: a cytochrome P450 (P450arom), the product of the cyp19 gene, and the ubiquitous flavoprotein NADPH (reduced nicotinamide adenine dinucleotide phosphate)-cytochrome P450 reductase (6, 7) . Aromatase activity in the brain was first detected by Frederick Naftolin and collaborators in fetal human limbic system and in the rat hypothalamus (8) (9) (10) (11) . After these pioneering findings, numerous studies have shown the expression, activity and distribution of aromatase in the central nervous system of several species of vertebrates (12-18) including humans (19) (20) (21) (22) (23) (24) .
Brain aromatase is thought to be involved in regulatory effects of androgens, via conversion to estrogens, on reproductive neuroendocrine development (25) (26) (27) (28) . In addition, local estrogen synthesis by neural tissue in adult life is involved in the regulation of synaptic function and neuronal plasticity (29) (30) (31) (32) (33) (34) (35) . Brain aromatase is rapidly modulated by afferent synaptic activity (36-39) and brain estrogen levels can be regulated within minutes by synaptic inputs. In turn, rapid changes in brain aromatase activity regulate the function of neuronal information processing (40, 41) and behavior (36) (37) (38) (39) 42) . In addition, the effects of locally synthesized estradiol on neuronal physiology might be relevant for the control of mood, affective status and cognition (43) .
Brain steroidogenesis under pathological conditions
Steroidogenesis in the nervous system is altered under neurodegenerative conditions as indicated by the increase in the levels of steroids, such as pregnenolone and progesterone, observed following traumatic injury in the brain and spinal cord (44) (45) (46) or by the modifications in the levels of several steroids in the brain and spinal cord of male and female rats with diabetic encephalopathy (47, 48) . Furthermore, proteins involved in the intramitochondrial trafficking of cholesterol, such as StAR and TSPO mentioned above, are upregulated in the central nervous system after injury (49) (50) (51) . The increased expression of StAR and TSPO after injury might be associated with an increase in steroidogenesis and could represent an adaptive response of the neural tissue. Indeed, steroids synthesized by the nervous system, such as pregnenolone and its metabolites progesterone, dihydroprogesterone and tetrahydroprogesterone, are neuroprotective (2, (52) (53) (54) (55) .
Neurodegenerative conditions and injury are also associated with an increase in the brain expression of aromatase (50, (56) (57) (58) . Multiple different forms of brain lesions, in both male and female animals, result in the induction of aromatase in reactive astrocytes located near neurodegenerative foci (56, (59) (60) (61) (62) (63) . Studies using specific aromatase inhibitors or aromatase knockout animals indicate that aromatase activity reduces neuronal death and gliosis in different experimental neurodegenerative models in vivo (43, 52, 59, (64) (65) (66) (67) (68) (69) (70) . Furthermore, the specific inhibition of the enzyme in the injured brain reduces tissue repair and increases neurodegeneration, indicating that brain aromatase is neuroprotective (59, 61, 63, 64, (71) (72) (73) (74) . Therefore, aromatase is a potential target for therapeutic approaches.
Interestingly, recent studies have identified 3-b-hydroxysterol d-24-reductase (DHCR24), the enzyme that catalyzes the synthesis of cholesterol from desmosterol, as one of the mediators of the neuroprotective actions of estradiol (75, 76) . DHCR24 is codified by seladin-1 (for Selective Alzheimer's Disease indicator-1) gene. Estradiol promotes the expression of seladin-1/DHCR24 gene via functionally active half-palindromic estrogen response element (ERE) contained in its promoter region and also by a mechanism involving insulinlike growth factor-1, a known mediator of the neuroprotective effects of the hormone (77, 78) . It has been proposed that by the enhancement of seladin-1 expression, estradiol might promote cholesterol synthesis, allowing an increased production of neuroprotective steroids by brain cells (76) . Indeed, it is known that estradiol promotes progesterone synthesis in the brain (79) . Therefore, estradiol produced in the brain by the enzyme aromatase could potentially impact on the local synthesis of other neuroprotective steroids.
An alternative to hormonal therapy for the brain: the modulation of steroidogenesis
Since some steroids produced by neural tissue are neuroprotective, a potential therapeutic approach to promote neuroprotection might be to increase the levels of neuroprotective steroids in the brain by modulating their local synthesis. Ligands for TSPO are available and at least some of them exert neuroprotective and anti-inflammatory effects in the brain of young animals (80, 81) and a beneficial effect on morphological parameters of the sciatic nerve of aged male rats (82, 83) . In addition to increasing the local synthesis of neuroprotective steroids, TSPO might have other functions which are also important in neuroprotection, such as the regulation of oxidative processes, since TSPO might modulate mitochondrial sensitivity to reactive oxygen species (84) . Reactive oxygen species have been implicated in neurodegeneration in several types of injury and these generally worsen during the aging process. Consequently, TSPO ligands might, in part, exert neuroprotection by directly reducing sensitivity to reactive oxygen species-induced damage.
Another step in brain steroidogenesis that can be targeted for neuroprotection is the conversion of testosterone in estradiol. The human aromatase gene is under the control of different tissue-specific promoters (85) and the promoters which are involved in the expression of aromatase in the human brain have been identified (24) . It is therefore conceivable that selective aromatase modulators (86) can be developed which will enhance the expression of aromatase and the consequent increase in estrogen formation in the brain but not in other tissues. However, we have very little information on the factors that regulate local estradiol formation in the human brain and how these factors might interfere with the neuroprotective, cognitive and affective effects of hormone therapy. Nevertheless, a recent study indicates that vitamin D and mifepristone enhance the activity of different aromatase promoters in human glioma cells, but not in human neuroblastoma and breast cancer cells (87) , suggesting that it would be possible to exert a cell-type selective modulation of estrogen biosynthesis within the human brain.
Finally, we have little information about local production of additional estrogens with differential effects on neuroprotection or recuperation. For example, the dihydrotestosterone metabolite, 5a-androstane-3b, 17b-diol has been shown to activate estrogen receptor b in hippocampal and hypothalamic neurons (88, 89) and plays a functional role in stress responses. The enzymes responsible for production of 3b-diol are present in the brain (90) , suggesting that the kinetics of binding and the role of this dihydrotestosterone metabolite in neuroprotection in various types of injury or other functions of estrogen receptor b should be examined further. Another estrogen, 17a-estradiol, has been demonstrated to be present at high levels in the mammalian brain (91) . Levels of 17a-estradiol do not decline following gonadectomy and adrenalectomy, and all of the known enzymes required for synthesis of this estrogen are present within the brain, sug-gesting that this enantiomer is produced in brain tissue. The levels of 17a-estradiol in brain tissue are both region-and age-dependent, and 17a-estradiol is neuroprotective in several different in vivo (92, 93) and in vitro (94, 95) models of neural injury. The neuroprotective effects of 17a-estradiol are generally considered to be due to its anti-oxidant properties. Factors that regulate the levels of 17a-estradiol in the nervous system should be explored.
Expert opinion
A crucial development in recent knowledge is the importance of local steroidogenesis for brain function. The importance of some of the steroidogenic pathways, despite having been studied for years, is still unclear in the human brain. The precise localization and regulation in the human central nervous system of steroidogenic enzymes and the importance of their activity for brain physiology and pathology has only begun to be unraveled. Here, we have reviewed a potential therapeutic alternative to promote neuroprotection, based on the protective effects of brain steroidogenesis. Potential candidates for pharmacological targeting include the proteins that are essential to steroidogenesis, such as those that participate in the transport of cholesterol from the cytoplasm to the inner mitochondrial membrane. TSPO ligands and other molecules that might enhance steroidogenesis in the nervous system should be systematically tested in animal models of neurodegeneration. Compounds that regulate the activity and expression of StAR, aromatase, seladin-1 and of other proteins involved in steroid synthesis and metabolism should also be explored and developed.
Outlook
A promising avenue for potential therapeutic tools that are being currently developed include, as highlighted above, new activators for steroidogenic enzymes, such as aromatase, and proteins that regulate steroidogenesis, such as StAR and TSPO. A primary goal will be to tailor these compounds to target not only specific tissues but also to direct these to individual regions and or cell types (i.e., neurons, astrocytes, microglia, oligodendrocytes) within the nervous system and provide optimal levels of the steroid which is most beneficial to prevent damage or promote recovery for each type of injury, whether acute or chronic. It will also be very important to determine whether changes in local brain production of steroids and the consequent changes in their brain levels affect the pharmacological actions of therapeutic compounds currently used for the treatment of affective and cognitive disorders, since any potential interference might be crucial for the outcome of these therapies.
Highlights
• The central nervous system is a steroidogenic tissue that expresses enzymes for steroid synthesis and metabolism, potentially providing endogenous ligand to activate neuroprotective pathways, and steroidogenesis in the nervous system is altered under neurodegenerative conditions. • A potential therapeutic approach to promote neuroprotection could be to increase local levels of neuroprotective steroids in the brain by modulating their local synthesis.
• The promising findings regarding site-and cell-specific activators of steroidogenic enzymes in the treatment of different forms of neural injury in experimental models merits a sustained research and development effort to create new therapies for neuronal protection and repair.
